Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antibiotics—metronidazole, penicillin, and tobramycin. Each component has a distinct mechanism of action and antimicrobial spectrum: - **Metronidazole** is a nitroimidazole antibiotic effective against anaerobic bacteria and certain protozoa. It works by disrupting DNA synthesis in susceptible organisms, leading to cell death[5][7]. - **Penicillin** refers to the class of beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in bacterial lysis[3][4]. - **Tobramycin** is an aminoglycoside antibiotic that binds irreversibly to the 30S subunit of bacterial ribosomes, inhibiting protein synthesis and causing cell death. It is particularly active against Gram-negative bacteria such as Pseudomonas aeruginosa[1][2][8]. This combination would provide broad-spectrum coverage against aerobic Gram-positive (penicillins), Gram-negative (tobramycin), and anaerobic organisms (metronidazole). Such combinations are sometimes used empirically for severe mixed infections or intra-abdominal infections where polymicrobial etiology is suspected.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metronidazole + penicillin + tobramycin.